Chart Industries Inc vs Merck & Co., Inc. — how do they compare? Chart Industries Inc trades at $209.97 (market cap $10.05B), while Merck & Co., Inc. trades at $125.94 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 30.4× Chart Industries Inc's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| GTLS | MRK | |
|---|---|---|
Market Cap | $10.05B | $305.29B |
Sector | Technology | Health |
52-Week High | $209.91 | $129.52 |
52-Week Low | $167.29 | $77.60 |
Enterprise Value | $13.57B | $348.71B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Trailing returns across standard periods
Latest headlines on both assets
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →